Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Adenocarcinoma of the lung, drawn from the whole corpus: 15 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 14 changes by month →When this page itself was last checked or edited.
Copy-number heterogeneity predicted recurrence or death with a hazard ratio of 4.
PFS HR 0.
Segmentectomy was superior to lobectomy for overall survival; in the pure-solid subgroup five-year overall survival was 92.
Median overall survival 14.
Median overall survival 20.